Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.620
-0.050 (-2.99%)
At close: Jul 31, 2025, 4:00 PM
1.610
-0.010 (-0.62%)
After-hours: Jul 31, 2025, 5:02 PM EDT
Elevation Oncology Employees
Immuron had 7 employees as of June 30, 2024. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
$578,327
Profits / Employee
-$650,022
Market Cap
11.04M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 7 | 1 | 16.67% |
| Jun 30, 2023 | 6 | 1 | 20.00% |
| Jun 30, 2022 | 5 | -11 | -68.75% |
| Jun 30, 2014 | 16 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMRN News
- 14 days ago - Immuron - FY25 global sales exceed projection, up 49% on prior year - GlobeNewsWire
- 2 months ago - Immuron Letter to Shareholders: Projects Update - GlobeNewsWire
- 4 months ago - Immuron Travelan® highest sales in history - GlobeNewsWire
- 5 months ago - Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - GlobeNewsWire
- 6 months ago - Immuron Travelan® continued strong sales growth - GlobeNewsWire
- 7 months ago - Immuron Announces New Research Collaboration targeting Antimicrobial Resistance - GlobeNewsWire
- 7 months ago - Immuron Announces Travelan® Clinical Trial Update - GlobeNewsWire
- 8 months ago - Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th - GlobeNewsWire